Skip Navigation


European Heart Journal Advance Access originally published online on January 9, 2006
European Heart Journal 2006 27(12):1495-1504; doi:10.1093/eurheartj/ehi706
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
27/12/1495    most recent
ehi706v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (8)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Helske, S.
Right arrow Articles by Lindstedt, K. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Helske, S.
Right arrow Articles by Lindstedt, K. A.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2006. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Possible role for mast cell-derived cathepsin G in the adverse remodelling of stenotic aortic valves

Satu Helske1, Suvi Syväranta1, Markku Kupari2, Jani Lappalainen1, Mika Laine3, Jyri Lommi2, Heikki Turto2, Mikko Mäyränpää1, Kalervo Werkkala4, Petri T. Kovanen1 and Ken A. Lindstedt1,*

1 Wihuri Research Institute, Kalliolinnantie 4, FIN-00140 Helsinki, Finland
2 Division of Cardiology, Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland
3 Minerva Institute for Medical Research, Helsinki, Finland
4 Division of Cardiothoracic Surgery, Department of Surgery, Helsinki University Central Hospital, Helsinki, Finland

Received 25 July 2005; revised 2 December 2005; accepted 8 December 2005; online publish-ahead-of-print 9 January 2006.

* Corresponding author. Tel: +358 9 681 411; fax: +358 9 637 476. E-mail address: ken.lindstedt{at}wri.fi

Aims Aortic stenosis (AS) is characterized by extensive remodelling of the valves, including infiltration of inflammatory cells, extracellular matrix degradation, and fibrosis. The molecular mechanisms behind this adverse remodelling have remained obscure. In this article, we study whether cathepsin G, an angiotensin II (Ang II)-forming elastolytic enzyme, contributes to progression of AS.

Methods and results Stenotic aortic valves (n=86) and control valves (n=17) were analysed for cathepsin G, transforming growth factor-ß1 (TGF-ß1), and collagens I and III with RT–PCR and immunohistochemistry. Valvular collagen/elastin ratio was quantified by histochemistry. In stenotic valves, cathepsin G was present in mast cells and showed increased expression (P<0.001), which correlated positively (P<0.001) with the expression levels of TGF-ß1 and collagens I and III. TGF-ß1 was also present in mast cell-rich areas and cathepsin G induced losartan-sensitive TGF-ß1 expression in cultured fibroblasts. Collagen/elastin ratio was increased in stenotic valves (P<0.001) and correlated positively with smoking (P=0.02). Nicotine in cigarette smoke activated mast cells and induced TGF-ß1 expression in cultured fibroblasts. Fragmented elastin was observed in stenotic valves containing activated cathepsin G-secreting mast cells and in normal valves treated with cathepsin G.

Conclusion In stenotic aortic valves, mast cell-derived cathepsin G may cause adverse valve remodelling and AS progression.

Key Words: Angiotensin • Aortic stenosis • Cathepsin G • Elastin • Fibrosis • Mast cell


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
K. Toutouzas, M. Drakopoulou, A. Synetos, E. Tsiamis, G. Agrogiannis, N. Kavantzas, E. Patsouris, D. Iliopoulos, S. Theodoropoulos, M. Yacoub, et al.
In Vivo Aortic Valve Thermal Heterogeneity in Patients With Nonrheumatic Aortic Valve Stenosis: The First In Vivo Experience in Humans
J. Am. Coll. Cardiol., August 26, 2008; 52(9): 758 - 763.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
S. Helske, T. Miettinen, H. Gylling, M. Mayranpaa, J. Lommi, H. Turto, K. Werkkala, M. Kupari, and P. T. Kovanen
Accumulation of cholesterol precursors and plant sterols in human stenotic aortic valves
J. Lipid Res., July 1, 2008; 49(7): 1511 - 1518.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
T. A. Miettinen and H. Gylling
Vascular effects of diets, especially plant sterol ester consumption.
J. Am. Coll. Cardiol., April 22, 2008; 51(16): 1562 - 1563.
[Full Text] [PDF]


Home page
Eur Heart JHome page
S. Helske, M. Laine, M. Kupari, J. Lommi, H. Turto, L. Nurmi, I. Tikkanen, K. Werkkala, K. A. Lindstedt, and P. T. Kovanen
Increased expression of profibrotic neutral endopeptidase and bradykinin type 1 receptors in stenotic aortic valves
Eur. Heart J., August 1, 2007; 28(15): 1894 - 1903.
[Abstract] [Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.